Zelira receives $919,000 R&D Tax Incentive Scheme Refund
Filed with ASX · · 2 pages · English
Zelira Therapeutics Ltd. on 6ix
Earlier from Zelira Therapeutics
- Appendix 4D & FY24 Interim Financial Report
- December 2023 Quarterly Activities Report
- HOPE SPV receives US$819,000 second tranche of funding
- September 2023 Quarterly Activities Report
- Zelira closes $3.25M funding as part of HOPE SPV fundraise
Later from Zelira Therapeutics
- March 2024 Quarterly Activities Report
- HOPE SPV receives US$681,000 third tranche of funding
- ZLD secures US$1.4M unsecured Chairman loan facility
- ZLD Advances HOPE Autism Drug Program with U.S FDA Meeting
- June 2024 Quarterly Activities Report
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics